EFFECT OF UPADACITINIB ON INTENSITY OF SCORAD ITEMS AND IMPACTS TO ITCH AND SLEEP: ANALYSIS FROM THE MEASURE UP 1 AND MEASURE UP 2 STUDIES

被引：0
|
作者：
Cameron, Michael [1 ]
Magnolo, Nina [2 ]
Prajapati, Vimal H. [3 ]
Haque, Adel [4 ]
Lee, Wan-Ju [5 ]
Altman, Katherine [5 ]
Platt, Andrew M. [5 ]
Lane, Michael C. [5 ]
Calimlim, Brian M. [5 ]
Taieb, Alain [6 ]
机构：
[1] Mt Sinai Hosp, Dept Dermatol, New York, NY USA
[2] Univ Hosp Munster, Dept Dermatol, Munster, Germany
[3] Univ Calgary, Div Dermatol, Dept Med, Calgary, AB, Canada
[4] Jefferson Hlth Northeast, Dept Med, Jefferson, AR USA
[5] AbbVie Inc, N Chicago, IL USA
[6] Univ Bordeaux, INSERM 1312, Bordeaux, France
来源：
ACTA DERMATO-VENEREOLOGICA | 2023年 / 103卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P10.18
引用
收藏
页码：56 / 57
页数：2
相关论文
共 50 条
  • [21] Efficacy and Safety of Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Measure Up 1, Measure Up 2, and AD Up Phase 3 Clinical Trials at 52 Weeks
    Paller, Amy
    Mendes-Bastos, Pedro
    Eichenfield, Lawrence
    Soong, Weily
    Lio, Peter
    Prajapati, Vimal
    Platt, Andrew
    Liu, John
    Ladizinski, Barry
    Thyssen, Jacob
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB157 - AB157
  • [22] The multidimensional burden of moderate-to-severe atopic dermatitis: a pooled analysis of baseline data from three phase III studies (Measure Up 1, Measure Up 2 and AD Up)
    Silverberg, J. I.
    Thyssen, J. P.
    Costanzo, A.
    Calimlim, B. M.
    Tenorio, A. R.
    Chen, N.
    Gooderham, M. J.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E126 - E127
  • [23] Effects of upadacitinib on the patient-reported impact of atopic dermatitis: Atopic Dermatitis Impact Scale (ADerm-IS) results from two pivotal phase 3 studies (MEASURE UP 1 and MEASURE UP 2)
    Simpson, Eric L.
    de Bruin-Weller, Marjolein S.
    Prajapati, Vimal H.
    Calimlim, Brian M.
    Teixeira, Henrique D.
    Zeng, Jiewei
    Liu, Meng
    Silverberg, Jonathan I.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB60 - AB60
  • [24] Effects of upadacitinib on the patient-reported impact of atopic dermatitis: Atopic Dermatitis Impact Scale (ADerm-IS) - results from two pivotal phase III studies (MEASURE UP 1 and MEASURE UP 2)
    Simpson, E. L.
    De Bruin-Weller, M. S.
    Prajapati, V. H.
    Calimlim, B. M.
    Teixeira, H. D.
    Zeng, J.
    Liu, M.
    Silverberg, J. I.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E124 - E124
  • [25] Effects of upadacitinib on patient-reported symptoms of atopic dermatitis: Atopic Dermatitis Symptom Scale (ADerm-SS) - results from two pivotal phase III studies (MEASURE UP 1 and MEASURE UP 2)
    Silverberg, J. I.
    Thyssen, J. P.
    Rosmarin, D.
    Pink, A. E.
    Calimlim, B. M.
    Teixeira, H. D.
    Hu, X.
    Yang, Y.
    Thaci, D.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E124 - E125
  • [26] Effects of upadacitinib on patient-reported symptoms of atopic dermatitis: Atopic Dermatitis Symptom Scale (ADerm-SS) results from two pivotal phase 3 studies (MEASURE UP 1 and MEASURE UP 2)
    Silverberg, Jonathan I.
    Thyssen, Jacob P.
    Rosmarin, David
    Pink, Andrew E.
    Calimlim, Brian M.
    Teixeira, Henrique D.
    Hu, Xiaofei
    Yang, Yang
    Thaci, Diamant
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB7 - AB7
  • [27] Upadacitinib with or without topical corticosteroids improves health-related quality of life in adolescent and adult patients with moderate-to-severe atopic dermatitis: results from three phase III studies (Measure Up 1, Measure Up 2 and AD Up)
    Prajapati, Vimal H.
    Rosmarin, David
    Shumack, Stephen
    Calimlim, Brian M.
    Takemoto, Shunya
    Hu, Xiaofei
    Ladizinski, Barry
    Warren, Richard B.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 (03) : E81 - E81
  • [28] Sustained improvements over 140 weeks in signs, symptoms, and quality of life with upadacitinib in adolescents and adults with moderate-to-severe atopic dermatitis: integrated results from the phase 3 Measure Up 1 and Measure Up 2 studies
    Prajapati, Vimal H.
    Bunick, Christopher G.
    Eyerich, Kilian
    Gold, Linda Stein
    Galimberti, Fabrizio
    Calimlim, Brian
    Teixeira, Henrique
    Hu, Xiaofei
    Yang, Yang
    Sancho, Cristina
    Grada, Ayman
    Irvine, Alan D.
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
  • [29] Safety and efficacy of upadacitinib monotherapy in adolescents and adults with moderate-to-severe atopic dermatitis: results from two pivotal, phase III, randomized, double-blinded, monotherapy, placebo-controlled studies (Measure Up 1 and Measure Up 2)
    Guttman-Yassky, E.
    Teixeira, H. D.
    Simpson, E. L.
    Papp, K. A.
    Pangan, A. L.
    Blauvelt, A.
    Thaci, D.
    Chu, C. Y.
    Hong, H. C.
    Katoh, N.
    Paller, A. S.
    Calimlim, B.
    Gu, Y.
    Hu, X.
    Liu, M.
    Yang, Y.
    Tenorio, A. R.
    Chu, A. D.
    Irvine, A. D.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 184 (03) : E62 - E62
  • [30] ABSOLUTE EASI TARGET IN MODERATE-TO-SEVERE ATOPIC DERMATITIS: ANALYSIS OF DATA FROM THE MEASURE UP 1 AND 2 STUDIES
    Prajapatil, Vimal
    Simpson, Eric L.
    Thyssen, Jacob P.
    Chovatiya, Raj
    Lane, Michael
    Teixeira, Henrique
    Calimlim, Brian
    Silverberg, Jonathan I.
    ACTA DERMATO-VENEREOLOGICA, 2022, 102 : 33 - 33
12345